Malignant neoplasm of other endocrine glands and related structures
In Malignant neoplasms of thyroid and other endocrine glands (C73-C75), chapter 2: Neoplasms
8 billable codes under C75: all are a CC; all map to HCC 23 (Prostate, Breast, and Other Cancers and Tumors), HCC 20 (Lung and Other Severe Cancers).A CC or MCC (major CC) is a secondary diagnosis that raises the MS-DRG payment. An HCC counts toward a Medicare Advantage patient's risk score.
Advertisements
Instructional notes
Excludes1: not coded here, use a different code
- malignant carcinoid tumors (C7A.0-)
- malignant neoplasm of adrenal gland (C74.-)
- malignant neoplasm of endocrine pancreas (C25.4)
- malignant neoplasm of islets of Langerhans (C25.4)
- malignant neoplasm of ovary (C56.-)
- malignant neoplasm of testis (C62.-)
- malignant neoplasm of thymus (C37)
- malignant neoplasm of thyroid gland (C73)
- malignant neuroendocrine tumors (C7A.-)
Official coding guidelines
From the ICD-10-CM Official Guidelines for Coding and Reporting, FY 2027 (CMS and NCHS). Links open the PDF at the right page.
Rules for coding benign and malignant neoplasms: using the Neoplasm Table, sequencing primary and secondary sites, treatment encounters, complications, and current cancer versus personal history.
- Admission/Encounter for treatment of primary site (page 33)
- Admission/Encounter for treatment of secondary site (page 33)
- Coding and sequencing of complications (page 34)
- Primary malignancy previously excised (page 34)
- Admissions/Encounters involving antineoplastic chemotherapy, immunotherapy and radiation therapy (page 35)
- Admission/encounter to determine extent of malignancy (page 36)
- Symptoms, signs, and abnormal findings listed in Chapter 18 associated with neoplasms (page 36)
- Admission/encounter for pain control/management (page 36)
All codes under C75
C75 can't be used on a claim. Pick a billable code below; grey headings group them.
- C75.0Malignant neoplasm of parathyroid gland
- C75.1Malignant neoplasm of pituitary gland
- C75.2Malignant neoplasm of craniopharyngeal duct
- C75.3Malignant neoplasm of pineal gland
- C75.4Malignant neoplasm of carotid body
- C75.5Malignant neoplasm of aortic body and other paraganglia
- C75.8Malignant neoplasm with pluriglandular involvement, unspecified
- C75.9Malignant neoplasm of endocrine gland, unspecified
C75 MS-DRGs
As the principal diagnosis, the billable codes under C75 group to these 8 MS-DRGs (v44.0). Which one applies depends on procedures performed, secondary diagnoses (CC/MCC), and the patient's age and discharge status.
- DRG 643 Endocrine Disorders with MCC (5 of 8 codes)
- DRG 644 Endocrine Disorders with CC (5 of 8 codes)
- DRG 645 Endocrine Disorders without CC/MCC (5 of 8 codes)
- DRG 054 Nervous System Neoplasms with MCC (3 of 8 codes)
- DRG 055 Nervous System Neoplasms without MCC (3 of 8 codes)
- DRG 146 Ear, Nose, Mouth and Throat Malignancy with MCC (1 of 8 codes)
- DRG 147 Ear, Nose, Mouth and Throat Malignancy with CC (1 of 8 codes)
- DRG 148 Ear, Nose, Mouth and Throat Malignancy without CC/MCC (1 of 8 codes)
Other codes that refer to C75
Notes on these codes point to C75.
About the condition
Plain-language background from MedlinePlus (National Library of Medicine), not coding guidance.
Cancer
Cancer is not just one disease but many diseases. Cancer begins in your cells, which are the building blocks of your body. Usually, your body forms new cells as needed, replacing old cells that die. Sometimes this process goes wrong. New cells grow even when you don't need them, and old cells don't die when they should. These extra cells can form a mass called a tumor.
Read more about cancer on MedlinePlusEndocrine Diseases
Your endocrine system includes eight major glands throughout your body. These glands make hormones. Hormones are chemical messengers. They travel through your bloodstream to tissues or organs. Hormones work slowly and affect body processes from head to toe. These include:
Read more about endocrine diseases on MedlinePlusCode history
Valid since FY2016, when ICD-10-CM took effect on October 1, 2015. No changes since.